Subscribe to Hospitalhealthcare’s news feed.
Click on “Follow” and decide if you want to get news from Hospitalhealthcare via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to Hospitalhealthcare comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from Hospitalhealthcare which you are really interested in. Click on the blue “Filter” button below to get started.
Title: Hospitalhealthcare
Is this your feed? Claim it!
Weekly subcutaneous obexelimab significantly prolongs time to disease flare, increases remission rates and reduces glucocorticoid requirements compared with placebo in patients with active immunoglobulin G4-related disease (IgG4-RD), a new trial has shown.
IgG4-RD is a chronic, systemic fibroinflammatory condition characterised by relapsing disease activity and potenti...
Repeated antibiotic exposure in early childhood may disrupt the developing gut microbiome and increase the risk of later inflammatory bowel disease (IBD), with the strongest association observed for Crohn’s disease, according to a recent study.
The incidence of childhood-onset IBD continues to rise in many countries, prompting growing interest in determining factors th...
Healthcare professionals are invited to register for a free ASK Uveal Melanoma webinar to discover more about the recognition, diagnosis and clinical significance of this rare disease that poses a significant challenge for clinicians.
Taking place on Thursday, 25 June 2026 fro...
The antisense oligonucleotide bepirovirsen, which targets hepatitis B virus (HBV) transcripts, achieved significantly higher rates of functional cure than placebo in two replicate phase 3 trials involving patients with chronic HBV infection receiving stable nucleos(t)ide analogue (NA) therapy.
Upadacitinib may offer a therapeutic option for patients with difficult-to-treat perianal Crohn’s disease (pCD) who have failed multiple advanced therapies, according to real-world data from a recent multicentre French cohort.
pCD is among the most challenging disease manifestations to manage, with limited evidence available to guide treatment beyond anti-tumour necros...